Transaction · 0001643653-26-000016

Benevich Eric

BENEVICH ERIC, CCO, reported an open-market or private sale at NEUROCRINE BIOSCIENCES INC involving 2154.000000 shares for an estimated $333029.94. Reported holdings after the transaction were 64408.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SCCO
NBIXNEUROCRINE BIOSCIENCES INC
Trade date
Sep 09, 2026
Filing date
Sep 11, 2026
View on SEC Insider profile
Disclosed value-$333kShares × reported price
Shares traded2.15k$154.61 per share
Holdings after64.4kDirect
% of reported position traded3.24%This security and ownership context
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 66,562 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

NBIX price since this filing

Daily closing prices, with the filing date and available return windows
NBIX · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +5.6%1w ago +1.0%1d ago -0.7%
Returns since7d -6.4%30d -8.8%90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001643653-26-000016
Common Stock
Transaction date
Sep 09, 2026
Filed Sep 11, 2026, 12:29 AM · 2d delay
Shares
2,154 sh
$154.61 per share
Estimated value
-$333k
Computed from shares × price
Holdings after
64,408 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Direct Ownership Large Sale 10b5-1 Detected
Filing-only score

0 points

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • timely_filing+4 points

    reporting_delay_days = 2

    Filing reported within two business days of the transaction.
  • tenb5_1_detected-10 points

    is_10b5_1 = true

    Stored filing content includes detected 10b5-1 language.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Commercial Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    Includes an aggregate of 178 shares purchased on February 27, 2026 and August 31, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.

  2. F2

    The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2026. Additionally,

  3. Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

  4. F3

    The option was granted February 6, 2017 and vested in 48 equal monthly installments beginning March 6, 2017. These options were due to expire on February 6, 2027.

Original filing · 0001643653-26-000016
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

NBIX